三阴性乳腺癌的组织学异质性:美国国家癌症中心数据库分析
基于美国国家癌症中心数据库(NCDB)2004至2012年数据,分析89,222例接受手术的三阴性乳腺癌(TNBC)患者,比较不同组织学亚型的总生存(OS)。结果显示,与浸润性导管癌(IDC)相比,化生性乳腺癌(MBC)OS更差(HR 1.39),髓样癌(MedBC)和腺样囊性癌(ACC)OS更好(HR 0.42和0.32),提示组织学亚型对TNBC预后有显著影响。
要点
- TNBC各组织学亚型的三阴性比例不同,MBC为74.1%、MedBC为60.6%、ACC为75.7%、ABC为50.1%、ILC为1.8%,IDC为14.0%(p<0.001)。
- 与IDC相比,MBC的OS更差(HR 1.39,p<0.001),MedBC(HR 0.42,p<0.001)和ACC(HR 0.32,p=0.003)的OS更好。
- MedBC和ACC接受肿块切除加放疗的比例较高(51.7%和51.5%),MBC和ILC较低(33.1%和25.4%),IDC为42.5%(p<0.001)。
核心结论
- TNBC的组织学异质性显著影响患者结局,可能有助于制定个体化治疗。
研究设计与样本
- 回顾性队列研究,利用美国国家癌症中心数据库(NCDB)2004至2012年数据,纳入89,222例接受手术的TNBC患者。
主要发现
- MBC、MedBC、ACC、ABC和ILC的三阴性比例与IDC显著不同(p<0.001)。
- TNBC在IDC和ILC中预测更差的总生存(p<0.001)。
- 与IDC相比,MBC的OS更差(HR 1.39,p<0.001),MedBC(HR 0.42,p<0.001)和ACC(HR 0.32,p=0.003)的OS更好。
- MedBC和ACC接受肿块切除加放疗的比例较高,MBC和ILC较低(p<0.001)。
关键数值与推荐
- 三阴性比例:MBC 74.1%、MedBC 60.6%、ACC 75.7%、ABC 50.1%、ILC 1.8%、IDC 14.0%(p<0.001)。
- 总生存HR:MBC 1.39(p<0.001)、MedBC 0.42(p<0.001)、ACC 0.32(p=0.003),参照IDC。
- 肿块切除加放疗比例:MedBC 51.7%、ACC 51.5%、MBC 33.1%、ILC 25.4%、IDC 42.5%(p<0.001)。
临床怎么用
- 在TNBC临床管理中应考虑组织学亚型对预后的影响。
- MBC亚型TNBC预后较差,可能需要更积极的治疗策略。
- MedBC和ACC亚型TNBC预后较好,治疗决策时可参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC. METHODS: A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan-Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome. RESULTS: MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p < 0.001). TNBC predicted an inferior OS in IDC (p < 0.001) and ILC (p < 0.001). Lumpectomy and radiation (RT) were more common in MedBC (51.7%) and ACC (51.5%) and less common in MBC (33.1%) and ILC (25.4%), when compared to IDC (42.5%, p < 0.001). TNBC patients with MBC (HR 1.39, p < 0.001), MedBC (HR 0.42, p < 0.001) and ACC (HR 0.32, p = 0.003) differed significantly in OS when compared to IDC. CONCLUSION(S): Our results indicate that histologic heterogeneity in TNBC significantly informs patient outcomes and thus, has the potential to aid in the development of optimum personalised treatments.
引用
- Mills MN, Yang GQ, Oliver DE, et al. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018. PMID: 29870876. doi:10.1016/j.ejca.2018.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。